{
  "image_filename": "table_p7_det_6_004.png",
  "image_path": "Hsiao_et_al.__2023_/extracted/figures/table_p7_det_6_004.png",
  "image_type": "Table",
  "page_number": 7,
  "block_id": "det_6_004",
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "supports_claim": false,
  "explanation": "Table presenting baseline demographic and clinical characteristics of participants in two vaccine groups (Recombinant Vaccine N=279,400 vs Standard-Dose Vaccine N=395,852 vs All Vaccinees N=675,252), including sex, race/ethnicity, coexisting illnesses, and receipt of previous year influenza vaccine. The table provides only participant baseline characteristics and contains no data on antibody responses or immunogenicity, and thus does not support the claim Note: No immunogenicity or antibody response outcomes are shown; only demographic and clinical baseline data are presented",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Table presenting baseline demographic and clinical characteristics of participants in two vaccine groups (Recombinant Vaccine N=279,400 vs Standard-Dose Vaccine N=395,852 vs All Vaccinees N=675,252), including sex, race/ethnicity, coexisting illnesses, and receipt of previous year influenza vaccine.",
    "evidence_found": null,
    "reasoning": "The table provides only participant baseline characteristics and contains no data on antibody responses or immunogenicity, and thus does not support the claim",
    "confidence_notes": "No immunogenicity or antibody response outcomes are shown; only demographic and clinical baseline data are presented"
  }
}